enGene Holdings Inc (Nasdaq: ENGN), a Canada-based clinical-stage genetic medicines company, announced on Tuesday that it has named Lee Giguere as its new chief legal officer and corporate secretary.

Giguere has earlier served as chief legal officer and secretary of Obsidian Therapeutics. He has worked as general counsel and secretary at Chiasma, deputy general counsel and assistant secretary at Karyopharm Therapeutics and served in roles at Boston Scientific Corporation and in the business law practice of Goodwin Procter LLP.

Jason D. Hanson, enGene chief executive officer, said: "I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer. His track record leading the legal function of successful companies, including those navigating late-stage development, product approvals, commercial launches, and strategic transactions, will strongly support our growth."